Clinical trial
Pharmacokinetic Characterization of Intramuscular Olanzapine Depot
NCT00094640 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00094640 |
|---|---|
| Title | Pharmacokinetic Characterization of Intramuscular Olanzapine Depot |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Intramuscular Olanzapine Depot |
| First posted | Oct 22, 2004 |
| Last update posted | Jul 19, 2006 |
| Countries | Australia, Belgium, Brazil, Croatia, Czechia, Mexico, Slovakia, Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: